Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture.
Avid Bioservices Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$26.00|
|52 Week High||US$6.99|
|52 Week Low||US$28.36|
|1 Month Change||17.81%|
|3 Month Change||4.21%|
|1 Year Change||243.92%|
|3 Year Change||400.00%|
|5 Year Change||1,002.49%|
|Change since IPO||32.65%|
Recent News & Updates
Is Avid Bioservices (NASDAQ:CDMO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Statutory Profit Doesn't Reflect How Good Avid Bioservices' (NASDAQ:CDMO) Earnings Are
When companies post strong earnings, the stock generally performs well, just like Avid Bioservices, Inc.'s...
|CDMO||US Biotechs||US Market|
Return vs Industry: CDMO exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: CDMO exceeded the US Market which returned 30.3% over the past year.
Stable Share Price: CDMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CDMO's weekly volatility (9%) has been stable over the past year.
About the Company
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization.
Avid Bioservices Fundamentals Summary
|CDMO fundamental statistics|
Is CDMO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CDMO income statement (TTM)|
|Cost of Revenue||US$69.08m|
Last Reported Earnings
Jul 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.10|
|Net Profit Margin||6.26%|
How did CDMO perform over the long term?See historical performance and comparison
Is Avid Bioservices undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CDMO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CDMO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CDMO is poor value based on its PE Ratio (251.8x) compared to the US Biotechs industry average (24x).
PE vs Market: CDMO is poor value based on its PE Ratio (251.8x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: CDMO is poor value based on its PEG Ratio (4x)
Price to Book Ratio
PB vs Industry: CDMO is overvalued based on its PB Ratio (35.7x) compared to the US Biotechs industry average (2.9x).
How is Avid Bioservices forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDMO's forecast earnings growth (63.6% per year) is above the savings rate (2%).
Earnings vs Market: CDMO's earnings (63.6% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CDMO's revenue (26.2% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CDMO's revenue (26.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CDMO's Return on Equity is forecast to be high in 3 years time (32.6%)
How has Avid Bioservices performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDMO has high quality earnings.
Growing Profit Margin: CDMO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CDMO has become profitable over the past 5 years, growing earnings by 37.5% per year.
Accelerating Growth: CDMO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CDMO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: Whilst CDMO's Return on Equity (28.65%) is high, this metric is skewed due to their high level of debt.
How is Avid Bioservices's financial position?
Financial Position Analysis
Short Term Liabilities: CDMO's short term assets ($200.8M) exceed its short term liabilities ($63.2M).
Long Term Liabilities: CDMO's short term assets ($200.8M) exceed its long term liabilities ($162.6M).
Debt to Equity History and Analysis
Debt Level: CDMO's debt to equity ratio (311%) is considered high.
Reducing Debt: Insufficient data to determine if CDMO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CDMO's debt is not well covered by operating cash flow (19.1%).
Interest Coverage: CDMO's interest payments on its debt are well covered by EBIT (8.7x coverage).
What is Avid Bioservices's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDMO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nick Green (56 yo)
Mr. Nicholas Stewart Green, also known as Nick, B.Sc., MBA, has been the President, Chief Executive Officer and Director at Avid Bioservices, Inc. since July 30, 2020. He served as the Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Nick's total compensation ($USD2.98M) is about average for companies of similar size in the US market ($USD3.49M).
Compensation vs Earnings: Insufficient data to compare Nick's compensation with company performance.
Experienced Management: CDMO's management team is considered experienced (3.3 years average tenure).
Experienced Board: CDMO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.
Avid Bioservices, Inc.'s employee growth, exchange listings and data sources
- Name: Avid Bioservices, Inc.
- Ticker: CDMO
- Exchange: NasdaqCM
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.595b
- Shares outstanding: 61.34m
- Website: https://www.avidbio.com
Number of Employees
- Avid Bioservices, Inc.
- 2642 Michelle Drive
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 23:09|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.